JMAC Enterprises’s Jazz Pharmaceuticals JAZZ Stock Holding History

JMAC Enterprises’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$652K	Hold	3,450	–	–	0.12%	80
2025 Q4	$587K	Hold	3,450	–	–	0.11%	82
2025 Q3	$455K	Hold	3,450	–	–	0.09%	93
2025 Q2	$366K	Sell	3,450 -250	-7%	-$27.2K	0.08%	98
2025 Q1	$459K	Hold	3,700	–	–	0.11%	91
2024 Q4	$456K	Hold	3,700	–	–	0.07%	136
2024 Q3	$412K	Hold	3,700	–	–	0.07%	141
2024 Q2	$395K	Hold	3,700	–	–	0.07%	139
2024 Q1	$446K	Sell	3,700 -500	-12%	-$61.2K	0.08%	126
2023 Q4	$517K	Hold	4,200	–	–	0.11%	121
2023 Q3	$544K	Sell	4,200 -600	-13%	-$79.9K	0.13%	116
2023 Q2	$595K	Hold	4,800	–	–	0.15%	109
2023 Q1	$702K	Hold	4,800	–	–	0.18%	102
2022 Q4	$765K	Hold	4,800	–	–	0.21%	100
2022 Q3	$640K	Hold	4,800	–	–	0.18%	110
2022 Q2	$749K	Sell	4,800 -600	-11%	-$92.4K	0.19%	106
2022 Q1	$841K	Hold	5,400	–	–	0.2%	98
2021 Q4	$758K	Buy	+5,400	New	+$710K	0.18%	101

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

JMAC Enterprises's JAZZ Position: Q1 2026 in Review

JMAC Enterprises held its Jazz Pharmaceuticals (JAZZ) position steady in Q1 2026 at 3,450 shares worth $652K. The position accounts for 0.12% of the portfolio, ranked #80.

JMAC Enterprises first reported a position in JAZZ in Q4 2021 and has held it in 18 quarters since. The position peaked at $841K in Q1 2022. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

JMAC Enterprises held 3,450 shares of Jazz Pharmaceuticals worth $652K as of Q1 2026.
JMAC Enterprises left its Jazz Pharmaceuticals share count unchanged in Q1 2026.
Jazz Pharmaceuticals made up 0.12% of JMAC Enterprises's portfolio in Q1 2026, its #80 holding.
JMAC Enterprises first reported a position in Jazz Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
JMAC Enterprises's Jazz Pharmaceuticals position peaked at $841K in Q1 2022.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on JMAC Enterprises's 13F filing for Q1 2026, filed 1 May 2026.